CNTX on Nasdaq

Context Therapeutics Inc.

American pharmaceutical preparations company based in Philadelphia.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerCNTX on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersPhiladelphia, United States
Incorporated inDE²
Business address2001 Market Street, Suite 3915 Unit #15, Philadelphia, Pa 19103²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴⁵⁶⁷-$39.7M in 2025+1444% since 2020

Net income³⁴⁵⁶⁷-$36.1M in 2025

Fiscal year	2020	2021	2022	2023	2024	2025
Operating income	-$2.6M³	-$10.5M⁴	-$15.4M⁵	-$25.1M⁶	-$29.9M⁷	-$39.7M⁷
Interest	$661.2K³	$64.2K³
Income tax	$0³	$0⁴	$0⁵	$0⁶	$0⁷	$0⁷
Net income	$6.6M³	-$10.5M⁴	-$14.8M⁵	-$24.0M⁶	-$26.7M⁷	-$36.1M⁷
Earnings per share	$3.07³	-$3.69⁴	-$0.93⁵	-$1.50⁶	-$0.46⁷	-$0.38⁷
Earnings per share (diluted)	-$3.96³	-$3.69⁴	-$0.93⁵	-$1.50⁶	-$0.46⁷	-$0.38⁷

Total assets³⁴⁵⁶⁷$68.5M in 2025+14556% since 2020

Total liabilities³⁴⁵⁶⁷$8.0M in 2025−17% since 2020

Shareholders’ equity³⁴⁵⁶⁷$60.5M in 2025

Cash³⁴⁵⁶⁷$66.0M in 2025+29024% since 2019

Fiscal year	2019	2020	2021	2022	2023	2024	2025	2026
Cash	$226.6K³	$290.7K³	$49.6M⁴	$35.5M⁵	$14.4M⁶	$94.4M⁷	$66.0M⁷
Current assets		$299.3K³	$51.3M⁴	$37.9M⁵	$16.0M⁶	$97.9M⁷	$68.4M⁷
Total assets		$467.3K³	$51.3M⁴	$38.0M⁵	$16.1M⁶	$98.1M⁷	$68.5M⁷
Current liabilities		$9.5M³	$3.0M⁴	$3.2M⁵	$4.2M⁶	$2.7M⁷	$8.0M⁷
Total liabilities		$9.6M³	$3.0M⁴	$3.2M⁵	$4.2M⁶	$2.9M⁷	$8.0M⁷
Shareholders’ equity	-$24.0M³	-$16.9M⁴	$48.3M⁵	$34.8M⁶	$11.9M⁷	$95.3M⁷	$60.5M⁷
Shares outstanding		331.8K shares³	16.0M shares⁴	16.0M shares⁵	16.0M shares⁶	89.7M shares⁷	91.9M shares⁷	91.9M shares⁷

Cash from operations³⁴⁵⁶⁷-$26.4M in 2025+2450% since 2020

Capital spending⁴⁵⁶⁷$33.9K in 2025

Free cash flow⁴⁵⁶⁷-$26.4M in 2025+200% since 2021

Fiscal year	2020	2021	2022	2023	2024	2025
Cash from operations	-$1.0M³	-$8.8M⁴	-$13.5M⁵	-$21.0M⁶	-$14.6M⁷	-$26.4M⁷
Capital spending		$0⁴	$36.8K⁵	$0⁶	$7.3K⁷	$33.9K⁷
Free cash flow		-$8.8M	-$13.6M	-$21.0M	-$14.6M	-$26.4M

Compare Context Therapeutics Inc. with another company

Leadership

Who has led Context Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Martin A. Lehr2021–now

Chief financial officer

Jennifer Lynn Minai-Azary2021–now

2025

Chief executive officerMartin A. Lehr Oct 19, 2021 to now¹⁰
Chief financial officerJennifer Lynn Minai-Azary Nov 1, 2021 to now¹¹

Board members and other officers (13)

Chief Medical OfficerKaren Deborah Chagin Jun 9, 2025 to now¹²
Chief Medical OfficerUllmann Claudio Dansky Aug 1, 2024 to now¹³
SVP of R&DEvan G. Dick Oct 19, 2021 to Dec 17, 2021¹⁴
Chief Medical OfficerTarek Sahmoud Oct 19, 2021 to Aug 17, 2022¹⁵
Head of CMC and RegulatoryWilliam F. Rencher Oct 19, 2021 to Dec 17, 2021¹⁶
Board memberAndy Pasternak Jan 14, 2025 to now¹⁷
Board memberKaren L. Smith Sep 5, 2024 to now¹⁸
Board memberLuke Nathaniel Walker Sep 5, 2024 to now¹⁹
Board memberJennifer Evans Stacey Oct 19, 2021 to now²⁰
Board memberLinda West Oct 19, 2021 to now²¹
Board memberMartin A. Lehr Oct 19, 2021 to now¹⁰
Board memberPhilip W. Kantoff Oct 19, 2021 to now²²
General counselAlex C. Levit Oct 19, 2021 to now²³

Former names

Context Therapeutics LLCMar 19, 2021 to May 3, 2021²

Timeline

Oct 19, 2021New chief executive Martin A. Lehr becomes CEO¹⁰

Filings

273 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 88 insider forms, 45 large holders, 1 private raises, 66 other. The latest 20:

Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 12, 2026SCHEDULE 13G/A EDGAR
Aug 5, 20268-K EDGAR
Aug 5, 202610-Q EDGAR
Jul 31, 20268-K EDGAR
Jul 31, 2026SCHEDULE 13G/A EDGAR
Jul 27, 2026SCHEDULE 13G EDGAR
Jun 26, 20264 EDGAR
Jun 26, 20264 EDGAR
Jun 26, 20264 EDGAR
Jun 26, 20264 EDGAR
Jun 26, 20264 EDGAR
Jun 26, 20264 EDGAR
Jun 26, 20268-K EDGAR
Jun 15, 20268-K EDGAR
May 18, 20268-K EDGAR
May 15, 2026SCHEDULE 13G/A EDGAR
May 14, 2026SCHEDULE 13G EDGAR
May 14, 2026SCHEDULE 13G/A EDGAR
May 12, 2026SCHEDULE 13G/A EDGAR

The 273 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 45 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

May 6, 2024Raised $100 million in a private offering of equity Form D: $100 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 78. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Nextech Invest Ltd.	7,419,355	$4.1M	0.2%	No change
Deep Track Capital, LP	7,419,355	$4.1M	0.1%	No change
Soleus Capital Management, L.P.	7,063,141	$3.9M	0.1%	+100,000
BlackRock, Inc.	6,169,250	$3.4M	0.0%	+5,322,554
Avidity Partners Management LP	4,998,267	$2.8M	0.4%	−4,998,267
Franklin Resources Inc	3,803,338	$2.1M	0.0%	No change
Vanguard Capital Management LLC	3,432,052	$1.9M	0.0%	+99
Octagon Capital Advisors LP	3,050,000	$1.7M	0.2%	−2,200,000
Blue Owl Capital Holdings LP	2,934,015	$1.6M	0.2%	−2,155,000
TCG Crossover Management, LLC	2,682,696	$1.5M	0.0%	No change
Geode Capital Management, LLC	1,830,309	$1.0M	0.0%	+1,226,542
State Street Corp	1,413,428	$782.9K	0.0%	+1,179,921
Mpm Bioimpact LLC	1,299,046	$719.5K	0.0%	−9,380,345
Renaissance Technologies LLC	1,041,399	$576.8K	0.0%	+858,400
ADAR1 Capital Management, LLC	750,969	$416.0K	0.0%	+399,875
Jane Street Group, LLC	645,209	$357.4K	0.0%	+208,278
Vanguard Portfolio Management LLC	638,878	$353.9K	0.0%	New
Northern Trust Corp	615,576	$341.0K	0.0%	+512,320
Vanguard Fiduciary Trust Co	433,888	$240.4K	0.0%	+92,544
Marshall Wace, Llp	384,528	$211.5K	0.0%	−2,563,913
XTX Topco Ltd	294,301	$163.0K	0.0%	New
Qube Research & Technologies Ltd	257,068	$142.4K	0.0%	+245,670
Charles Schwab Investment Management Inc	227,850	$126.2K	0.0%	New
Pathstone Holdings, LLC	214,875	$119.0K	0.0%	+104,631
Timothy G. Youngquist 2020 Irrevocable Trust	198,384	$109.9K	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARContext Therapeutics Inc. filings on SEC EDGAR
2
SEC EDGARContext Therapeutics Inc. filings on SEC EDGAR
3
SEC EDGARContext Therapeutics Inc. 10-K for fiscal 2020
4
SEC EDGARContext Therapeutics Inc. 10-K for fiscal 2021
5
SEC EDGARContext Therapeutics Inc. 10-K for fiscal 2022
6
SEC EDGARContext Therapeutics Inc. 10-K for fiscal 2023
7
SEC EDGARContext Therapeutics Inc. 10-K for fiscal 2024
8
SEC EDGARContext Therapeutics Inc. 10-Q for fiscal 2026
9
SEC EDGARContext Therapeutics Inc. 10-Q for fiscal 2026
10
SEC EDGARMartin A. Lehr, Chief executive officer
11
SEC EDGARJennifer Lynn Minai-Azary, Chief financial officer
12
SEC EDGARKaren Deborah Chagin, Chief Medical Officer
13
SEC EDGARUllmann Claudio Dansky, Chief Medical Officer
14
SEC EDGAREvan G. Dick, SVP of R&D
15
SEC EDGARTarek Sahmoud, Chief Medical Officer
16
SEC EDGARWilliam F. Rencher, Head of CMC and Regulatory
17
SEC EDGARAndy Pasternak, Board member
18
SEC EDGARKaren L. Smith, Board member
19
SEC EDGARLuke Nathaniel Walker, Board member
20
SEC EDGARJennifer Evans Stacey, Board member
21
SEC EDGARLinda West, Board member
22
SEC EDGARPhilip W. Kantoff, Board member
23
SEC EDGARAlex C. Levit, General counsel